Serina Therapeutics (SER) Stock Analysis

What Serina Therapeutics does

Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.

Key metrics

ETFs linked to SER

Broad-market and Healthcare sector ETFs an investor holding Serina Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SER fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Serina Therapeutics?

Serina Therapeutics trades under the ticker SER on AMEX.

Which exchange is SER listed on?

SER is listed on AMEX.

What sector does Serina Therapeutics operate in?

Serina Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SER in a portfolio?

PortView shows SER's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.